Accolade Inc (ACCD)

$6.51

+0.08

(+1.24%)

Market is closed - opens 7 PM, 13 Jun 2024

Insights on Accolade Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 93.22M → 124.83M (in $), with an average increase of 8.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -38.40M → -7.50M (in $), with an average increase of 84.5% per quarter

  • Vs HQY

    In the last 1 year, Healthequity Inc has given 35.6% return, outperforming this stock by 88.0%

  • Vs HQY

    In the last 3 years, Healthequity Inc has given 10.7% return, outperforming this stock by 98.8%

Performance

  • $6.45
    $6.74
    $6.51
    downward going graph

    1.0%

    Downside

    Day's Volatility :4.38%

    Upside

    3.41%

    downward going graph
  • $6.33
    $15.36
    $6.51
    downward going graph

    2.76%

    Downside

    52 Weeks Volatility :58.79%

    Upside

    57.62%

    downward going graph

Returns

PeriodAccolade IncSector (Health Care)Index (Russel 2000)
3 Months
-31.67%
-0.5%
0.0%
6 Months
-33.3%
9.6%
0.0%
1 Year
-52.41%
11.8%
0.0%
3 Years
-87.91%
17.5%
-24.3%

Highlights

Market Capitalization
528.1M
Book Value
$5.71
Earnings Per Share (EPS)
-1.33
Wall Street Target Price
13.0
Profit Margin
-24.09%
Operating Margin TTM
-6.35%
Return On Assets TTM
-8.4%
Return On Equity TTM
-21.71%
Revenue TTM
414.3M
Revenue Per Share TTM
5.53
Quarterly Revenue Growth YOY
26.1%
Gross Profit TTM
165.3M
EBITDA
-71.2M
Diluted Eps TTM
-1.33
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.21
EPS Estimate Next Year
-1.13
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    69%Buy
    30%Hold
    0
    0%Sell
Based on 23 Wall street analysts offering stock ratings for Accolade Inc(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
15
Hold
7
7
7
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 99.69%

Current $6.51
Target $13.00

Company Financials

FY19Y/Y Change
Revenue
94.8M
↑ 23.41%
Net Income
-56.5M
↓ 7.82%
Net Profit Margin
-59.59%
↑ 20.18%
FY20Y/Y Change
Revenue
132.5M
↑ 39.76%
Net Income
-51.4M
↓ 9.08%
Net Profit Margin
-38.76%
↑ 20.83%
FY21Y/Y Change
Revenue
170.4M
↑ 28.57%
Net Income
-50.7M
↓ 1.39%
Net Profit Margin
-29.73%
↑ 9.03%
FY22Y/Y Change
Revenue
310.0M
↑ 81.98%
Net Income
-123.1M
↑ 143.08%
Net Profit Margin
-39.71%
↓ 9.98%
FY23Y/Y Change
Revenue
363.1M
↑ 17.13%
Net Income
-459.7M
↑ 273.32%
Net Profit Margin
-126.58%
↓ 86.87%
FY24Y/Y Change
Revenue
414.3M
↑ 14.09%
Net Income
-99.8M
↓ 78.29%
Net Profit Margin
-24.09%
↑ 102.49%
Q4 FY22Q/Q Change
Revenue
90.9M
↑ 3.77%
Net Income
-39.9M
↓ 14.3%
Net Profit Margin
-43.84%
↑ 9.24%
Q1 FY23Q/Q Change
Revenue
99.0M
↑ 8.88%
Net Income
-30.4M
↓ 23.67%
Net Profit Margin
-30.73%
↑ 13.11%
Q2 FY23Q/Q Change
Revenue
93.2M
↓ 5.86%
Net Income
-38.4M
↑ 26.21%
Net Profit Margin
-41.2%
↓ 10.47%
Q3 FY23Q/Q Change
Revenue
96.9M
↑ 3.9%
Net Income
-32.8M
↓ 14.54%
Net Profit Margin
-33.89%
↑ 7.31%
Q4 FY23Q/Q Change
Revenue
99.4M
↑ 2.59%
Net Income
-21.1M
↓ 35.83%
Net Profit Margin
-21.2%
↑ 12.69%
Q1 FY24Q/Q Change
Revenue
124.8M
↑ 25.62%
Net Income
-7.5M
↓ 64.36%
Net Profit Margin
-6.01%
↑ 15.19%
FY19Y/Y Change
Total Assets
65.8M
↑ 39.68%
Total Liabilities
296.4M
↑ 28.43%
FY20Y/Y Change
Total Assets
124.4M
↑ 89.19%
Total Liabilities
148.2M
↓ 50.0%
FY21Y/Y Change
Total Assets
475.5M
↑ 282.2%
Total Liabilities
84.7M
↓ 42.87%
FY22Y/Y Change
Total Assets
1.3B
↑ 170.35%
Total Liabilities
429.7M
↑ 407.59%
FY23Y/Y Change
Total Assets
903.1M
↓ 29.75%
Total Liabilities
429.3M
↓ 0.11%
FY24Y/Y Change
Total Assets
788.2M
↓ 12.73%
Total Liabilities
342.7M
↓ 20.17%
Q4 FY22Q/Q Change
Total Assets
913.8M
↓ 1.92%
Total Liabilities
427.8M
↑ 0.58%
Q1 FY23Q/Q Change
Total Assets
903.1M
↓ 1.17%
Total Liabilities
429.3M
↑ 0.34%
Q2 FY23Q/Q Change
Total Assets
875.7M
↓ 3.03%
Total Liabilities
421.5M
↓ 1.81%
Q3 FY23Q/Q Change
Total Assets
854.3M
↓ 2.44%
Total Liabilities
416.7M
↓ 1.15%
Q4 FY23Q/Q Change
Total Assets
785.5M
↓ 8.06%
Total Liabilities
350.8M
↓ 15.82%
Q1 FY24Q/Q Change
Total Assets
788.2M
↑ 0.34%
Total Liabilities
342.7M
↓ 2.3%
FY19Y/Y Change
Operating Cash Flow
-16.5M
↓ 56.78%
Investing Cash Flow
-3.1M
↓ 56.41%
Financing Cash Flow
48.8M
↑ 224.71%
FY20Y/Y Change
Operating Cash Flow
-34.2M
↑ 106.96%
Investing Cash Flow
-3.5M
↑ 12.92%
Financing Cash Flow
28.2M
↓ 42.21%
FY21Y/Y Change
Operating Cash Flow
-25.2M
↓ 26.32%
Investing Cash Flow
-2.4M
↓ 31.18%
Financing Cash Flow
428.4M
↑ 1417.91%
FY22Y/Y Change
Operating Cash Flow
-62.4M
↑ 147.11%
Investing Cash Flow
-263.6M
↑ 10779.61%
Financing Cash Flow
257.9M
↓ 39.79%
FY23Y/Y Change
Operating Cash Flow
-40.7M
↓ 34.72%
Investing Cash Flow
-7.2M
↓ 97.26%
Financing Cash Flow
3.2M
↓ 98.77%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.7M
↑ 56.77%
Investing Cash Flow
-1.9M
↑ 17.1%
Financing Cash Flow
1.6M
↓ 534.32%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.6M
↓ 45.46%
Investing Cash Flow
-2.4M
↑ 26.27%
Financing Cash Flow
418.0K
↓ 73.99%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.3M
↑ 653.69%
Investing Cash Flow
-3.3M
↑ 36.18%
Financing Cash Flow
4.5M
↑ 964.83%
Q3 FY23Q/Q Change
Operating Cash Flow
-8.0M
↓ 58.32%
Investing Cash Flow
-3.3M
↑ 0.0%
Financing Cash Flow
641.0K
↓ 85.6%

Technicals Summary

Sell

Neutral

Buy

Accolade Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Accolade Inc
Accolade Inc
-10.82%
-33.3%
-52.41%
-87.91%
-78.35%
Solventum Corp
Solventum Corp
-10.45%
-18.18%
-18.18%
-18.18%
-18.18%
Veeva Systems Inc.
Veeva Systems Inc.
-7.78%
7.33%
-1.3%
-38.14%
12.56%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-7.76%
3.73%
-4.51%
23.56%
23.56%
Healthequity Inc
Healthequity Inc
12.34%
24.35%
35.61%
12.87%
25.94%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Accolade Inc
Accolade Inc
NA
NA
NA
-1.21
-0.22
-0.08
NA
5.71
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
54.57
54.57
1.35
4.76
0.13
0.06
NA
30.25
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
21.76
21.76
20.11
4.27
0.22
0.06
0.0
16.23
Healthequity Inc
Healthequity Inc
94.5
94.5
2.29
2.19
0.04
0.03
NA
24.11
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Accolade Inc
Accolade Inc
Buy
$528.1M
-78.35%
NA
-24.09%
Solventum Corp
Solventum Corp
Hold
$10.8B
-18.18%
NA
15.73%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$29.9B
12.56%
54.57
22.34%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$34.2B
23.56%
21.76
8.05%
Healthequity Inc
Healthequity Inc
Buy
$7.6B
25.94%
94.5
7.71%

Institutional Holdings

  • Brown Advisory Holdings Inc

    7.46%
  • BlackRock Inc

    7.22%
  • ARK Investment Management LLC

    7.16%
  • Vanguard Group Inc

    6.90%
  • JPMorgan Chase & Co

    6.80%
  • Bellevue Group AG

    6.13%

Company Information

accolade is a personalized health and benefits solution that dramatically improves the experience, outcomes and cost of healthcare for employers, health plans and their members. with a unique blend of compassionate advisors, clinical experts and intelligent technologies, we engage individuals and families in their health, establish trust, and influence their decisions at every stage of care. we’ve been recognized as one of the nation’s 25 most promising companies by forbes magazine, the fastest-growing private healthcare company by inc. 500, and a top workplace by multiple news publications. for more information, visit www.accolade.com.

Organization
Accolade Inc
Employees
2400
CEO
Mr. Rajeev Singh
Industry
Health Services

FAQs